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Abstract 
Objective: The aim of this study was to investigate the clinical usefulness of amrubicin therapy for 
patients with nongastrointestinal (GI) non-pancreatic extrapulmonary neuroendocrine carcinoma 
(EP-NEC).  
Methods: The medical records of patients from the 2 participating institutions were retrospectively 
reviewed. The eligibility criteria were: patients with non-GI non-pancreatic EP-NEC who received 
amrubicin monotherapy after platinum-based chemotherapy. Patients in whom the platinum-free 
interval (interval betweenthe last day of platinum administration and the first subsequent 
documentation of disease progression) was 90 days or longer were classified into the platinum-
sensitive group. 
Results: The study was conducted in a total of 13 patients identified as eligible. The response rate 
was 45.4% (5/11). The median progression-free survival and overall survival were 6.0 and 10.6 
months, respectively. A platinum-free interval of ≥ 90 days was identified as a significant predictor 
of a longer progression-free survival time. Grade 3 or 4 neutropenia was observed in 61.5% (8/13) of 
the patients. One patient died of treatment-related febrile neutropenia. 
Conclusions: Amrubicin monotherapy as second-line chemotherapy after failure of first-line 
platinum-based chemotherapy showed good efficacy in patients with non-GI non-pancreatic EP-
NEC. Neutropenia was encountered as the most serious adverse event. 
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Introduction 
Neuroendocrine neoplasms have been classified into 3 grades: low-, intermediate- and high-grade 
[1]. The low to intermediate-grade neuroendocrine neoplasms are usually termed neuroendocrine 
tumors (NETs), while the high-grade neoplasms are termed neuroendocrine carcinomas (NECs) 
because of the distinct clinicopathological differences between the entities [2]. Historically, NETs 
have been divided into gastrointestinal NETs (GI-NETs), pancreatic NETs (pNETs) and other NETs, 
whereas NECs are divided into pulmonary and extrapulmonary NECs (EP-NECs) because a majority 
of the NECs arise from the lung [3]. As EP-NECs arising from the GI tract and pancreas are usually 
discussed in relation to GI-NETs and pNETs, respectively, the other EP-NECs (non-GI non-
pancreatic EP-NEC) that arise from various organs are extremely rare, accounting for 0.1–0.4% of 
all cancers [4], and remain cancers with unmet need. EP-NEC was first described in 1930 [5]. 
Because of its low incidence and consequent difficulty in conducting large-scale randomized clinical 
studies, no standard treatment has been established yet for this disease. Therefore, chemotherapeutic 
regimens employed for small-cell lung cancer (SCLC) are often used to treat patients with advanced 
EP-NEC, based on expert consensus [6]. That is, a platinum agent combined with either etoposide or 
irinotecan is recognized as putative standard first-line chemotherapy for patients with advanced EP-
NEC [7, 8]. The combination of cisplatin and etoposide has been reported to yield an overall 
response rate (ORR) of 41% and a median progression-free survival time (PFS) of 8.9 months in 41 
patients with EP-NECs [9]. Combined therapy with cisplatin and irinotecan has been shown to yield 
an ORR of 50% and a median PFS of 4.8 months in 44 patients with these tumors [10]. The 
efficacy/safety of second-line chemotherapies for this disease have, however, not been fully 
elucidated. Amrubicin, a potent topoisomerase II inhibitor, was approved in Japan for the treatment 
of SCLC in 2002. Single-agent treatment with amrubicin was shown to be effective as second-line 
chemotherapy for patients previously treated with platinum-containing chemotherapy in the first-line 
setting. Onoda et al. [11] reported excellent results, including an ORR of 50% and a median overall 
survival time (OS) of 10.3 months in a platinum-refractory relapse group, and corresponding figures 
of 52% and 11.6 months in a platinum-sensitive relapse group. Furthermore, randomized phase II 
and III studies have revealed equivalent efficacy of the agent to that of platinum re-challenge or 
topotecan [12, 13]. Therefore, it was considered that amrubicin monotherapy may exert some 
beneficial activity in the second-line setting even in patients with EP-NEC. While 2 published 
studies have suggested the efficacy of amrubicin as second-line chemotherapy in patients with GI 
and pancreatic NEC [14, 15], we failed to find any reports of studies conducted to evaluate the 
efficacy of amrubicin for non-GI non-pancreatic EP-NEC in the second- or later-line setting. The 
present retrospective study was aimed at determining the efficacy and safety of amrubicin 
monotherapy in patients with recurrent EP-NEC after first-line platinum-based chemotherapy. 
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Patients and Methods 
Patients 
Eligible patients were extracted from the databases of the Department of Medical Oncology, Chiba 
University Hospital, and the Department of Breast and Medical Oncology, National Cancer Center 
Hospital. The eligibility criteria for inclusion in the study were patients diagnosed as having non-GI 
non-pancreatic EPNEC between January 2008 and January 2016 who had received at least 1 cycle of 
amrubicin monotherapy after failure of platinumbased chemotherapy. Patients with well-
differentiated carcinoma and Merkel-cell carcinoma were excluded because these conditions are 
established as distinct clinical entities. 
Methods 
All data were retrospectively collected from the patients’ medical records and images. The diagnosis 
had been confirmed by histopathology in either participating hospital. In all patients, amrubicin was 
administered at a dose of 40 mg/m 2 on days 1–3 of each treatment cycle of 3 weeks, in general, 
until documentation of disease progression. Dose reduction and/or treatment postponement due to 
toxicity were left to the discretion of the treating physicians. Tumor response was assessed according 
to the Response Evaluation Criteria in Solid Tumors (RECIST) ver1.1, and the toxicity was graded 
according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.  
Statistical Analysis and Ethical Considerations 
The aim of the study was to investigate efficacy and safety of amrubicin monotherapy in non-GI 
non-pancreatic EP-NEC patients with failure of platinum-based chemotherapy. OS was defined as 
the interval from day 1 of administration of amrubicin to the day of death. PFS was defined as the 
interval from day 1 of administration of amrubicin to the day of documentation of recurrence, 
disease progression, or death. Platinum-free interval (PFI) was defined as the duration from the last 
day of administration of a platinum agent as first-line chemotherapy to the day of documentation of 
disease progression. The patients were divided into 2 groups according to the PFI: the platinum-
sensitive relapse group (PFI ≥ 90 days) and the platinum-refractory relapse group (PFI < 90 days). 
The OS and PFS times were calculated from Kaplan-Meier curves. Univariate analysis was 
performed using the log-rank test. All statistical analyses were conducted using JMP (Ver. 11). The 
study was conducted with the approval of the institutional review boards of the 2 institutions. 
Informed consent from the patients was not required for obtaining approval from the institutional 
review boards, because of the retrospective nature and anonymous design of the study. 
 
Results 
Patient Characteristics 
In total, 13 patients were enrolled into the study, and their characteristics are shown in Table 1. The 
median age was 62 years (range 43–86), and 5 (38.5%) of the patients were male. The primary sites 
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of the tumors included the genitourinary tract in 4 patients, gynecological organs in 2 patients, 
thymus in 2 patients, and other sites in the remaining 5 patients. At initial diagnosis, 4 patients had 
locoregional lesions, while the remaining 9 had distant metastases. The first-line chemo- or 
chemoradiotherapy included cisplatin in 9 patients and carboplatin in the remaining 4 patients; the 
ORR to this therapy was 69.2%. The relapse was classified as platinum-sensitive relapse in 8 
(61.5%) patients. 
Drug Delivery 
Amrubicin was administered in the second- and third-line settings in 10 (76.9%) and 3 (23.1%) 
patients, respectively. Because of the retrospective nature of the present study, tumor response could 
not be evaluated according to RECIST ver. 1.1 in 1 patient who had not undergone adequate imaging 
studies and 1 patient who had bone metastases only. The response rate in the remaining 11 patients 
was 45.4% (95% confidence interval [CI], 21.3–72.0). The median PFS (Fig. 1a) and OS (Fig. 1b) 
were 6.0 (95% CI, 1.0–8.3) and 10.6 months (95% CI, 3.0–40.8), respectively. The 1-year survival 
rate was 47.2%. Univariate analysis revealed that sensitive relapse, as compared to refractory 
relapse, was a significant prognostic factor for PFS and OS. The median PFS was significantly 
different between the groups with sensitive and refractory relapse (7.2 months [95% CI, 3.4–8.3] vs. 
1.3 months [95% CI, 0.5–3.9]; p = 0.0022) (Fig.1c). However, no significant difference in the 
median OS was observed between the 2 groups (13.2 months [95% CI, 4.1–40.9] vs. 10.6 months 
[95% CI, 0.5–10.6]; p = 0.0822) (Fig. 1d).  
Toxicity 
All grade 3 or 4 adverse events are listed in Table 2. Severe neutropenia was recorded in 8 (61.5%) 
patients. Febrile neutropenia was observed in 3 (23.1%) patients. Treatment-related death occurred 
in 1 patient with febrile neutropenia complicated by sepsis. 
 
Table 1: Patient characteristics 
 
Variables  Number of patients (n = 13) (%) 
Age, median [range] 62 [43-86]  
Sex Male 5 38.5 
 Female 8 61.5 
Performance status 0 3 23.1 
 1 8 61.5 
 2 2 15.4 
 6 
Disease stage  Locoregional  4 30.8 
at diagnosis Metastatic 9 69.2 
Primary site Bladder 2 15.4 
 Thymus 2 15.4 
 Uterine cervix 1 7.7 
 Vagina 1 7.7 
 Kidney 1 7.7 
 Thyroid 1 7.7 
 Lachrymal gland 1 7.7 
 Prostate 1 7.7 
 Unknown 3 23.1 
First line regimen Cisplatin-based 9 69.2 
  Carboplatin- based 4 30.8 
Treatment of AMR  Second line 10 76.9 
 Third line 3 23.1 
 
PR, partial response; SD, stable disease; AMR, amrubicin 
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Table 2: Adverse events (n = 13) 
 
Grade 3 Grade 4 
Neutropenia 3 (23.1%) 5 (38.5%) 
Anemia 3 (23.1%) 2 (15.4%) 
Thrombocytopenia 1 (7.7%) 1 (7.7%)  
Febrile neutropenia 2 (15.4%) 1 (7.7%) 
Nausea 0 0 
Appetite loss  0 0 
 
  
Figure 1a 
 
 
Figure 1b 
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Figure 1c 
 
 
Figure 1d 
 
Figure legend  
Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS), showing a 
median PFS of 6.0 months (95% confidence interval [CI], 1.0–8.3) (a) and a median OS of 10.6 
months (95% CI, 3.0–40.8) (b). The PFS curves, according to the platinum-free interval (PFI) of 
first-line chemotherapy, reveals a significantly better median PFS in the platinum-sensitive relapse 
group (7.2 months; 95% CI, 3.4–8.3) than in the platinum-refractory relapse group (1.3 months; 95% 
CI, 0.5–3.9; p value = 0.0022) (c). The OS curves, according to the PFI of first-line chemotherapy, 
also reveal a significantly better median OS in the platinum-sensitive cases (13.2 months; 95% CI, 
4.1–40.9) than in the platinum-refractory cases (10.6 months; 95% CI, 0.5–10.6; p value =0.0822) 
(d). The vertical lines indicate censored cases. 
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Discussion  
In this retrospective study conducted to evaluate the efficacy and safety of amrubicin monotherapy 
for non-GI non-pancreatic EP-NEC patients with disease recurrence after previous first-line 
treatment with platinum-based chemotherapy, the ORR was 45.4%, and the median PFS and OS 
were 6.0 and 10.6 months, respectively. In patients with SCLC ( n = 424), amrubicin as second-line 
treatment has been shown to yield a response rate of 31.1%, and a median PFS and OS of 4.1 and 7.5 
months, respectively [13]. On the other hand, Nio et al. [14] reported a case series of 13 patients with 
GI-NEC in whom amrubicin monotherapy yielded an ORR of 38.5%, and a median PFS and OS of 
107 and 215 days, respectively. Ando et al. [15] reported a study of 10 patients with GI or pancreatic 
NEC in whom amrubicin monotherapy yielded an ORR of 20%, and median PFS and OS of 2.6 and 
5.0 months, respectively. Although it is difficult to compare the results because of the small sample 
sizes, the present results appear to suggest equivalent or better efficacy of amrubicin monotherapy in 
the second- or later-line setting against non-GI non-pancreatic EP-NEC than that reported for other 
EP-NECs. Some reports suggest possible differences in the efficacy depending on the primary sites 
of the tumors. For example, Cicin et al. [16] reported that the OS was significantly superior in 
patients with extrapulmonary small-cell carcinoma to that in those with SCLC. Haider et al. [17] 
reported that patients with small-cell cancer of the gynecologic site or genitourinary tract showed a 
better prognosis than those with small-cell cancer of the GI tract; the median OS in patients with 
small-cell cancer of the gynecological, genitourinary, and GI tract were 54.4, 10.8, and 4.4 months, 
respectively. Therefore, the clinical course of patients with NEC might differ according to the 
primary site of the tumor. The response rate and median PFS following treatment with amrubicin 
were 40.9% and 5.5 months, respectively, in the platinum-sensitive SCLC, while they were 20.1% 
and 2.8 months, respectively, in the platinum-refractory SCLC group [13]. In patients with SCLC, 
the role of chemotherapy in platinum-refractory relapse remains unclear. 
In the present study, PFI ≥ 90 days was identified as a significant prognostic factor for the PFS. Most 
of the adverse events could be tolerated, except in 1 patient, who died from febrile neutropenia with 
sepsis. Febrile neutropenia and grade 3 or 4 neutropenia were recorded in 23.1% (3/13) and 61.5% 
(8/13) of the patients, respectively. The limitations of the study were its retrospective nature and 
small sample size. Lack of a central pathology review was another shortcoming. Although all of 
these factors are critical to draw definitive conclusions, the present study, we believe, is the first to 
elucidate the efficacy efficacy and toxicity of amrubicin in patients with non-GI non-pancreatic EP-
NEC in the second-line setting. In conclusion, amrubicin shows good efficacy in non-GI non-
pancreatic EP-NEC patients with disease progression after previous first-line platinum-containing 
chemotherapy. When using amrubicin treatment, the attending physician should pay close attention 
to the possible occurrence of grade 3 or 4 neutropenia and febrile neutropenia. 
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